124 results
Page 2 of 7
8-K
EX-99.2
cc9efqe
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-10.1
p6wpc9m1e sl
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.3
byme93ezqxqma4 4x
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-10.2
zlev32sr0 mb76y1pry
31 Aug 20
Departure of Directors or Certain Officers
4:36pm
8-K
EX-99.1
m8xfw4mq6ai 3ynxo
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
4iwq1u94w
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
hvxl02
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
kaz6sy1o7 2sh2dduxy
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
emvpxhu 3o
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
nunfucdpy1eth8p 9s
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
b6prarf
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
m2ess4 bk9
2 Mar 20
Other Events
7:05am
S-3ASR
rgc0 agz8lks1bf3n
26 Feb 20
Automatic shelf registration
8:35am
8-K
EX-99.1
ywxntl4x xwaj
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
iqyr0e2tem3i6mz1d
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.1
9m4zei5w6 urz
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.2
cvxykk q8yi4s00sy
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am